The quest for optimal control of relapses in children with nephrotic syndrome

Affiliations

¹ Department of Pediatric Nephrology, Amalia Children's Hospital, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: anne.schijvens@radboudumc.nl.
² Pediatric Nephrology, Children's and Adolescents Hospital, University Hospital of Cologne, Cologne, Germany; Faculty of Medicine, University of Cologne, Cologne, Germany.
³ Department of Pediatric Nephrology, Amalia Children's Hospital, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.

Free article

Comment

Anne M Schijvens et al. Kidney Int. 2019 Mar.

Free article

. 2019 Mar;95(3):717.

doi: 10.1016/j.kint.2019.01.002.

¹ Department of Pediatric Nephrology, Amalia Children's Hospital, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: anne.schijvens@radboudumc.nl.
² Pediatric Nephrology, Children's and Adolescents Hospital, University Hospital of Cologne, Cologne, Germany; Faculty of Medicine, University of Cologne, Cologne, Germany.
³ Department of Pediatric Nephrology, Amalia Children's Hospital, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.

No abstract available

Comment on

Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.
Sinha A, Puraswani M, Kalaivani M, Goyal P, Hari P, Bagga A. Sinha A, et al. Kidney Int. 2019 Jan;95(1):210-218. doi: 10.1016/j.kint.2018.08.039. Epub 2018 Nov 26. Kidney Int. 2019. PMID: 30497684 Clinical Trial.